Cardiovascular Drugs and Therapy 2009-06-01

Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al.

Michael H Davidson

Index: Cardiovasc. Drugs Ther. 23(3) , 187-8, (2009)

Full Text: HTML

Abstract

Related Compounds

Related Articles:

Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs.

2006-07-01

[Eur. J. Pharmacol. 540(1-3) , 139-46, (2006)]

NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1.

2010-01-01

[J. Endocrinol. 1st ed., 204 , 47-56, (2010)]

Evaluation of induction potency of new drug candidates on CYP1A2 and CYP3A4 using real-time one-step RT-PCR in primary cultures of cryopreserved human hepatocytes.

2009-01-01

[Drug Metab. Pharmacokinet. 24(5) , 446-50, (2009)]

NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.

2006-02-01

[Metab. Clin. Exp. 55(2) , 151-8, (2006)]

NO-1886, a lipoprotein lipase activator, attenuates vascular smooth muscle contraction in rat aorta.

2007-01-12

[Eur. J. Pharmacol. 554(2-3) , 183-90, (2007)]

More Articles...